Reservoir Neuroscience, Inc.

SAN FRANCISCO, CA · Founded 2019 · Biotech · Private

Therapeutics designed to heal the blood-brain barrier

Claim this profile

Follows are private to you and power your alerts

Updated · reservoirneuro.com

Sector
Biotech
Headquarters
SAN FRANCISCO, CA
Founded
2019
Latest Form D
$3M, Jun 2026
Total capital
$9M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$9M
3 Form D · last Jun 2026
4 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
2
8 pending · first 2025
Rank in peer group#397 of 1449

Capital timeline

202120222023202420252026FEDERAL ↑EQUITY ↓Cumulative $9M1st Form D$3.9M2nd Form D$2.1M3rd Form D$3M
202120222023202420252026FEDERAL ↑EQUITY ↓Cumulative $9M1st Form D$3.9M3rd Form D$3M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$3M
  • Private capital raisedForm D · SEC · 2nd filing$2.1M
  • Private capital raisedForm D · SEC · 1st filing$3.9M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#397 · top 27%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Aaron FriedmanExecutive Officer, DirectorNamed in SEC Form D filings
  • Brian SlingerlandDirectorNamed in SEC Form D filings
  • James SummersDirectorNamed in SEC Form D filings
  • Patrick BurgermeisterDirectorNamed in SEC Form D filings
  • Tracy SaxtonDirectorNamed in SEC Form D filings
  • Vladimir SenatorovExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 10
Show all 10 patent records
  • EP2 Antagonist CompoundsMay 12, 2026 · US 12,624,024Granted
  • EP2 Antagonist CompoundsJun 12, 2025 · Application 19056593Pending
  • EP2 Antagonist CompoundsMay 13, 2025 · US 12,297,171Granted
  • EP2 Antagonist CompoundsApplication PCTUS2022034901Pending
  • EP2 Antagonist CompoundsApplication 19477755Pending
  • EP2 Antagonist CompoundsApplication 63214635Pending
  • EP2 Antagonist CompoundsApplication 63214645Pending
  • EP2 Antagonist CompoundsApplication PCTUS2022034903Pending
  • EP2 Antagonist CompoundsApplication 63435738Pending
  • EP2 Antagonist CompoundsApplication 63435730Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .